Infusionstherapie und klinische Ernährung
-
Infusionsther Klin Ernahr · Apr 1980
[Pharmacokinetics of middle-molecular hydroxyethyl starch (HAS 200/0,5].
The pharmacokinetics of middle molecular weight hydroxyethyl starch (HES; MW 200,000, Mn: 35,000, MW/Mn = 5.71, MS = 0.50) were examined in two groups of normovalaemic subjects. Subjects in group 1 (non-fasted) were administered an approximately equal dose of HES, twice as rapidly as subjects in group 2 (fasted pre- and postinjection). The intravascular half-life (IT50) of HES in groups 1 and 2 was 2.7 +/- 1.3 and 3.9 +/- 1.1 (SD), respectively. 96 h post-injection, 2% of the initially measured HES 200/0.5 concentration remained in the serum of group 1 subjects. ⋯ Similar changes occurred in the molecular size distribution of HES polymers excreted in the urine of these subjects. The erythrocyte sedimentation rate was not significantly affected by the presence of large quantities of HES 200/0.5 in the blood. The results of this preliminary study in normal man has shown that HES 200/0.5 appears to be an ideal volemic colloid for clinical situations requiring restoration of a diminished plasma volume of short duration.